“INDISCRIMINATE USE OF GLP-1 ANALOGUES, SUCH AS SEMAGLUTIDE (OZEMPIC®), FOR AESTHETIC PURPOSES AND MULTIDISCIPLINARY ACTION IN CARE AND RISK PREVENTION”. Editora Impacto Científico, Oct. 2025, pp. 342-56, https://periodicos.newsciencepubl.com/editoraimpacto/article/view/9073.